the ADBL report

Issue #139, July 2024

An Official Accompaniment to the Alberta Drug Benefit List (ADBL) produced by Alberta Blue Cross

The Expert Committee on Drug Evaluation and Therapeutics (ECDET)

In this issue:

Brief Summary of Drug Review Activities

The Expert Committee on Drug Evaluation and Therapeutics met on May 13 & 14, 2024. The Committee reviewed Manufacturer submissions for twenty-four (24) Drug Products for potential listing, or change in listing, on the *ADBL*.

In addition to Drug Products reviewed by the Expert Committee, twenty-two (22) Drug Products and Devices underwent Expedited Review for listing on the *ADBL* effective June 1, 2024, and eighteen (18) Drug Products and Devices underwent Expedited Review for listing on the *ADBL* effective July 1, 2024.

The following are highlights of recent changes to the *ADBL* and other topics of general interest. A complete list of changes, as well as the full *ADBL* may be accessed at https://www.ab.bluecross.ca/dbl/publications.php

Highlights of Products Originally Reviewed by Canada's Drug Agency (CDA-AMC)

The following Drug Products were reviewed by CDA-AMC and the Expert Committee and added to the *ADBL* effective May 24, 2024:

- **PAXLOVID* 150 mg/100 mg tablet pack & 150 mg/100 mg tablet pack (for moderate renal impairment)** (nirmatrelvir/ritonavir) (PFI) via Restricted Benefit/Special Authorization (SA)

A complete list of changes, as well as the full ADBL may be accessed at https://www.ab.bluecross.ca/dbl/publications.php.
Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).*

ABC 81171 (07/2024)

The following Drug Products were reviewed by CDA-AMC and the Expert Committee and added to the *ADBL* effective June 1, 2024:

- **LIVTENCITY* 200 mg tablet** (maribavir) (TAK) via SA
- **VYALEV* 12 mg/mL/ 240 mg/mL injection** (foslevodopa/ foscarbidopa) (ABV) via SA

The following Drug Product was reviewed by CDA-AMC and the Expert Committee and added to the *ADBL* effective June 13, 2024:

- **VABYSMO* 6 mg/0.05 mL vial injection** (faricimab) (HLR) via Restricted Benefit for the indications of Diabetic Macular Edema (DME) & Neovascular (wet) Age-related Macular Degeneration (nAMD)

Highlights of Drug Products Added

The following Drug Product was added to the *ADBL* effective June 1, 2024:

- **GLATIRAMER ACETATE* 20 mg/mL injection syringe** (glatiramer acetate) (MYP) via SA

Highlights of Biosimilar Drug Products Added

The following Biosimilar Drug Products were added to the *ADBL* effective June 1, 2024:

- **NYPOZI* 300 mcg/0.5 mL & 480 mcg/0.8 mL injection syringes** (filgrastim) (TNX) via SA
- **RYMTI* 50 mg/mL auto injector syringe & injection syringe** (etanercept) (LPC) via SA for the indications of Ankylosing Spondylitis (AS), Plaque Psoriasis (PsO), Polyarticular Juvenile Idiopathic Arthritis (pJIA), Psoriatic Arthritis (PsA) and Rheumatoid Arthritis (RA)

The following Biosimilar Drug Products were added to the *ADBL* effective July 1, 2024:

- **HYRIMOZ* 20 mg/0.2 mL injection syringe** (adalimumab) (SDZ) via SA for the indication of pJIA
- **HYRIMOZ* 40 mg/0.4 mL injection pen & syringe** (adalimumab) (SDZ) via SA for the indications of AS, adult Hidradenitis Suppurativa (HS), adult Crohn's Disease (CD), PsO, pJIA, PsA, RA & adult Ulcerative Colitis (UC)
- **HYRIMOZ* 80 mg/0.8 mL injection pen & syringe** (adalimumab) (SDZ) via SA for the indications of adult HS, adult CD, PsO & adult UC

A complete list of changes, as well as the full ADBL may be accessed at https://www.ab.bluecross.ca/dbl/publications.html.

Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).*

ABC 81171 (07/2024)